Sitanux 50 Tablet 10

About Sitanux 50 Tablet 10

Sitanux 50 Tablet 10 is used to manage Type 2 Diabetes by increasing insulin release and decreasing glucagon levels in the blood, which helps lower blood sugar after meals. By stabilizing blood sugar levels, it helps reduce the risk of long-term diabetic complications such as kidney damage, nerve pain, and vision problems. It is often prescribed when diet and exercise alone are not enough to maintain healthy glucose levels.

Frequently Asked Questions (FAQs)

What is Sitanux 50 Tablet 10 used for?

Sitanux 50 Tablet 10 is used to manage high blood sugar in adults with type 2 diabetes when diet, exercise, and single medicinal therapy are inadequate.

How does Sitanux 50 Tablet 10 work?

Sitanux 50 Tablet 10 contains sitagliptin, which works by regulating insulin levels and controlling high blood sugar.

Can I take Sitanux 50 Tablet 10 with other antidiabetic medicines?

Yes, Sitanux 50 Tablet 10 can be taken with other antidiabetic medications, such as metformin and sulfonylureas, but always consult your doctor first.

Are there any side effects of taking Sitanux 50 Tablet 10?

Common side effects include upper respiratory tract infection, nasopharyngitis, headaches, and hypoglycaemia.

How should I take Sitanux 50 Tablet 10?

Take Sitanux 50 Tablet 10 orally as advised by your doctor. It can be taken with or without food at any time of the day.

What precautions should I take while using Sitanux 50 Tablet 10?

Inform your doctor if you have or have ever had pancreatitis, gallstones, kidney disease, heart disease, or high triglyceride levels before starting this medicine.

Can I drink alcohol while on Sitanux 50 Tablet 10?

Alcohol can increase the risk of hypoglycaemia, especially if you are already taking other antidiabetic medicines. It is advisable to avoid consuming alcohol while on Sitanux 50 Tablet 10.

References

U.S. Food and Drug Administration. (2023, Oct). Zituvio (sitagliptin) tablets label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211566s000lbl.pdf
U.S. Food and Drug Administration. (2022, Jun). Januvia (sitagliptin) tablets label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021995s050lbl.pdf
U.S. Food and Drug Administration. (2006, Oct 16). Drug Approval Package - Januvia (sitagliptin phosphate) tablets. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000TOC.cfm
AHFS Patient Medication Information [Internet]. (2024, Feb 15). Sitagliptin – MedlinePlus Drug Information. U.S. National Library of Medicine. https://medlineplus.gov/druginfo/meds/a606023.html
National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 4369359, Sitagliptin. https://pubchem.ncbi.nlm.nih.gov/compound/Sitagliptin
Scott L. J. (2017). Sitagliptin: A Review in Type 2 Diabetes. Drugs, 77(2), 209–224. https://doi.org/10.1007/s40265-016-0686-9
Gallwitz B. (2007). Review of sitagliptin phosphate: a novel treatment for type 2 diabetes. Vascular health and risk management, 3(2), 203–210. https://doi.org/10.2147/vhrm.2007.3.2.203

Disclaimer

We, at Truemeds make a diligent attempt to deliver accurate, expert- drafted and thoroughly reviewed medicine related information to our consumers. However, it should, by no means, be considered a substitute for prescription from a certified doctor or a trustworthy doctor-patient relationship. In fact we detest any form of self medication without expert advice. The sole purpose of the information on our portal is to educate our consumers, which helps improve the communication between a doctor and a patient. The information by no means is complete in its entirety and should not be used to diagnose or treat any medical condition. No amount of information can replace the experience and expertise of a doctor, therefore his/her advice always holds priority and should be followed appropriately.